SCHEMBL12781109

SCHEMBL12781109

Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1-c1nc2ccccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.58
▸ HSD17B10 Q99714 1/20 0.53
▸ CCNB2 O95067 5/20 0.52
▸ CDK1 P06493 5/20 0.52
▸ CCNB1 P14635 5/20 0.52
▸ CCNB3 Q8WWL7 5/20 0.52
▸ JAK2 O60674 6/20 0.51
▸ EIF2AK2 P19525 3/20 0.47
▸ AURKA O14965 2/20 0.47
▸ CDK4 P11802 2/20 0.47
▸ CCNA2 P20248 2/20 0.47
▸ CCND1 P24385 2/20 0.47
▸ CDK2 P24941 2/20 0.47
▸ MAPK3 P27361 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ KDR P35968 2/20 0.47
▸ CSNK1A1 P48729 2/20 0.47
▸ CSNK1D P48730 2/20 0.47
▸ CSNK1E P49674 2/20 0.47
▸ CLK1 P49759 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13963586 0.89 BACE1 (0.55) BACE1HSD17B10CCNB2CDK1CCNB1
SCHEMBL12779078 0.86 BACE1 (0.63) BACE1MAPK1KITJAK1TYK2
SCHEMBL12781108 0.83 HSD17B10 (0.53) BACE1HSD17B10CCNB2CDK1CCNB1
SCHEMBL12781005 0.76 BACE1 (0.59) BACE1CCNB2CDK1CCNB1CCNB3
SCHEMBL12780937 0.76 BACE1 (0.58) BACE1CCNB2CDK1CCNB1CCNB3
SCHEMBL4037722 0.75 FLT3 (0.68) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL12780858 0.74 FLT3 (0.66) BACE1JAK2AURKAMAPK1KIT
SCHEMBL21067547 0.74 CCNB2 (0.67) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL27691113 0.74 JAK2 (0.55) CCNB2CDK1CCNB1CCNB3JAK2
SCHEMBL4991374 0.74 BACE1 (1.00) BACE1AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885HSD17B10 4060/4885CCNB2 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback